The demand for single-use bioprocessing technology has witnessed an increase over the years, owing to the rise in demand for continuous bio-production in the biopharmaceutical industries. Various market players constantly strive to develop innovative treatment solutions; hence, focus on adopting novel single-use bioprocessing technologies. The continuous demand for single use systems boost the market growth.
According to a new report published by Allied Market Research, titled, “Single-use Bioprocessing Market by Product, Application, Method, and End User: Global Opportunity Analysis and Industry Forecast, 2017-2023,” the global single-use bioprocessing market was valued at $2,800 million in 2016, and is projected to reach $9,342 million by 2023, growing at a CAGR of 18.7% from 2017 to 2023. The media bags & containers segment accounted for one-fourth share of the global market in 2016.
Single-use bioprocessing employs disposable technologies for the development and manufacturing of pharmaceutical products such as vaccines, monoclonal antibodies (mAbs), personalized medicine, and others. The adoption of single-use bioprocessing products has witnessed significant increased during the developmental stages of drugs and manufacturing of several biopharmaceuticals. This product has revolutionized the upstream as well as downstream processes of manufacturing drugs making it faster, simpler, and cheaper.
Get the PDF brochure of this market study@ https://www.alliedmarketresearch.com/request-sample/2359
Factors that boost the growth of single-use bioprocessing market include increase in demand for biopharmaceuticals, rise in adoption of disposable technologies, low risk of product cross-contamination attributed to SUB technologies, and less floor space requirement. However, certain aspects such as, extractability and leachability issues and stringent regulations pertaining to use of disposable systems in biopharmaceutical industry hamper the market growth.
Single-use bioprocessing technology has gained significant traction in the recent years, owing to the rapid adoption of disposable bioprocessing equipment by pharmaceutical manufacturers. These products have also proved beneficial for the small scale pharmaceutical manufacturers. Hence, most biopharmaceutical companies utilize single-use bioprocessing technology for manufacturing vaccines, monoclonal antibodies, and other pharmaceutical components on commercial scale.
Drivers, Restraints, and Opportunities
The impact of the driving factors is expected to overshadow that of the restraints. Moreover, increase in focus toward mergers, acquisitions, and product launches offer lucrative opportunities for the expansion of the global single-use bioprocessing market.
The report provides a comprehensive analysis of the key players operating in the global single-use bioprocessing market such as Thermo Fisher Scientific, Danaher Corporation, GE Healthcare (General Electric Company), Sartorius Stedim Biotech S.A, Merck Millipore (Merck Group), 3M Company, Eppendorf AG, Finesse Solutions, Inc., Applikon Biotechnology B.V., and Cesco Bioengineering Co., Ltd.
The other key players in the value chain include Octane Biotech Inc., PBS Biotech, Inc., Meissner Filtration Products, Inc., Sentinel Process Systems Inc., CMC Biologics (Asahi Glass Co.), Novasep, PendoTECH, and BioPure Technology Ltd.